Henan Tianfu Chemical Co., Ltd.
China
Product Name: Acyclovir
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson
Email: info@tianfuchem.com

59277-89-3

59277-89-3 structure

Name: Acyclovir
Chemical Name: acyclovir
CAS Number: 59277-89-3
Molecular Formula: C₈H₁₁N₅O₃
Molecular Weight: 225.205
Catalog: API Synthetic anti-infective drugs Antiviral drugs
Create Date: 2018-04-03 08:00:00
Modify Date: 2026-06-30 15:31:15
Acyclovir, a molecule tailored to inactivate the thymidine kinase of the herpesvirus, is a guanosine analogue antiviral drug. It is a drug for HSV infection by GlaxoSmithKline.IC50 Value: 0.53-0.75 uM [3]Target: HSVin vitro: Acyclovir sensitivity was determined in a plaque-reduction assay in Vero cells. IC50 Values were consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains were 2-10-fold less sensitive than Type 1 strains [2]. in vivo: two patients experienced a recurrence during treatment with oral acyclovir (200 mg 4 times daily) for up to 12 weeks, compared with nine during placebo treatment (P = 0.016). There was no difference between acyclovir and placebo in the time to the next recurrence following completion of treatment [3]. low-dose oral acyclovirmay be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of acyclovir prophylaxis for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections [4].Clinical trial: Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda. Phage2

Name	acyclovir
Synonyms	Valaciclovir Impurity B 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-6h-purin-6-one Zovir EINECS 261-685-1 aclovir Acyclovir (Aciclovir) 9-(2-HYDROXYETHOXYMETHYL)GUANINE(ACYCLOVIR) bw248u Acyclo-V 9-(2-Hydroxyethoxy)methylguanine Zovirax cream Zoviax Aciclovir Aciclovir (Acyclovir) Acycloguanosine/Acyclovir wellcome-248u Aciclovir for peak identification 1 2-Amino-9-((2-hydroxyethoxy)methyl)-1H-purin-6(9H)-one Aciclovir for peak identification 2 Azone 2-Amino-9-[(2-hydroxyethoxy)methyl]-1,9-dihydro-6H-purin-6-one 9-[(2-Hydroxyethoxy)methyl]guanine Acyclovir 24 2000 Wellcome 248U 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-6h-purin-6-on Acyclovir (Patented-No Supply) Cargosil Acyclovir Micronized 37 Acycloguanosine,9-[(2-Hydroxyethoxy)methyl]guanine, Acyclovir 9-[(2-Hydroxyethoxy)methyl]-1,9-dihydro-2-amino-6H-purin-6-one vipral Herpevir ACYCLOVIR, PHMA 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(2-hydroxyethoxy)methyl 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)-methyl)-6h-purin-6-on cycloguanosine virorax Acicloftal AcycL Acyclovir (base and/or unspecified salts) ACICLOVIR; ACYCLOGUANOSINE; ZOVIRAX 9-((2-Hydroxyethoxy)methyl)guanine Poviral 2-Amino-9-((2-hydroxyethoxy)Methyl)-1H-purin-6(9H)-one Aciclovir for system suitability Valacyclovir Impurity B (Acyclovir)B) ACETYLTHIAZOLE acielovir Acycolguanosine Maynar Acyclovir API 2-amino-9-[(2-hydroxyethoxy)methyl]-3,9-dihydro-6H-purin-6-one acyclovir &BP (Normal powder,Micro-powder) Vimrax Acyclovir (also product ID A1096) aciclovirum(latin) A Silowe Zyclir Cycloviran Valacyclovir Impurity B N(9)-Oxyethoxymethylguanine (Acyclovir) Viroraxl w-248-u BW 248U 2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one ovir Aciclovir COS Zovirax 2-AMINO-9-(2-HYDROXY-ETHOXYMETHYL)-1,9-DIHYDRO-PURIN-6-ONE 9-(2-Hydroxyethyloxymethyl)guanine ACYCLOVIR ACYCLOVIR SUBST ACV MFCD00057880 Acycloguanosine ACYCLOGUANOSINE Acyclovir solution,100ppm Acycloguanosine 9-[(2-Hydroxyethoxy)methyl]guanine Aciclovir Gerpevir ACICLOVIR

Description	Acyclovir, a molecule tailored to inactivate the thymidine kinase of the herpesvirus, is a guanosine analogue antiviral drug. It is a drug for HSV infection by GlaxoSmithKline.IC50 Value: 0.53-0.75 uM [3]Target: HSVin vitro: Acyclovir sensitivity was determined in a plaque-reduction assay in Vero cells. IC50 Values were consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains were 2-10-fold less sensitive than Type 1 strains [2]. in vivo: two patients experienced a recurrence during treatment with oral acyclovir (200 mg 4 times daily) for up to 12 weeks, compared with nine during placebo treatment (P = 0.016). There was no difference between acyclovir and placebo in the time to the next recurrence following completion of treatment [3]. low-dose oral acyclovirmay be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of acyclovir prophylaxis for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections [4].Clinical trial: Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda. Phage2
Related Catalog	Signaling Pathways >> Anti-infection >> HSV Research Areas >> Infection
References	[1]. Li Z, et al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7. [2]. Shelley WB, Hashim M, Shelley ED. Acyclovir in the treatment of hand-foot-and-mouth disease. Cutis. 1996 Apr;57(4):232-4. [3]. Collins P, Oliver NM. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir. J Antimicrob Chemother. 1986 Oct;18 Suppl B:103-12. [4]. Meyrick Thomas RH, Dodd HJ, Yeo JM, Oral acyclovir in the suppression of recurrent non-genital herpes simplex virus infection. Br J Dermatol. 1985 Dec;113(6):731-5. [5]. Tang IY, Maddux MS, Veremis SA, Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy. Transplant Proc. 1989 Feb;21(1 Pt 2):1758-60.

Density	1.8±0.1 g/cm3
Boiling Point	576.5±58.0 °C at 760 mmHg
Melting Point	256-257°C
Molecular Formula	C₈H₁₁N₅O₃
Molecular Weight	225.205
Flash Point	302.4±32.3 °C
Exact Mass	225.086182
PSA	119.05000
LogP	-3.31
Vapour Pressure	0.0±1.7 mmHg at 25°C
Index of Refraction	1.762
Stability	Stable. Incompatible with strong oxidizing agents.
Water Solubility	H2O: 0.7 mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UP0791400

CHEMICAL NAME :: 6H-Purin-6-one, 1,9-dihydro-2-amino-9-((2-hydroxyethoxy)methyl)-

CAS REGISTRY NUMBER :: 59277-89-3

LAST UPDATED :: 199712

DATA ITEMS CITED :: 30

MOLECULAR FORMULA :: C8-H11-N5-O3

MOLECULAR WEIGHT :: 225.24

WISWESSER LINE NOTATION :: T56 BN DN FN HNJ D1O2Q GZ IQ &T56 BN DN FVM INJ B1O2Q HZ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 28 mg/kg/2D-I

TOXIC EFFECTS :: Brain and Coverings - changes in surface EEG Behavioral - hallucinations, distorted perceptions Lungs, Thorax, or Respiration - sputum

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 12 mg/kg/1D-I

TOXIC EFFECTS :: Brain and Coverings - meningeal changes Behavioral - somnolence (general depressed activity) Behavioral - antipsychotic

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 100 mg/kg/5D-I

TOXIC EFFECTS :: Skin and Appendages - dermatitis, allergic (after systemic exposure)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 80 mg/kg/4D-I

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - hallucinations, distorted perceptions Behavioral - convulsions or effect on seizure threshold

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 486 mg/kg/17D-I

TOXIC EFFECTS :: Gastrointestinal - decreased motility or constipation Gastrointestinal - other changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 134 ug/kg/1D-I

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 101 mg/kg/2D-I

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Behavioral - muscle contraction or spasticity

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 107 mg/kg/4D-I

TOXIC EFFECTS :: Behavioral - hallucinations, distorted perceptions Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Multiple routes

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 36 mg/kg/2D-I

TOXIC EFFECTS :: Brain and Coverings - other degenerative changes Behavioral - coma Lungs, Thorax, or Respiration - other changes

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >20 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 860 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 620 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 750 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >10 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 724 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1118 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1118 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - species unspecified

DOSE/DURATION :: 400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 250 mg/kg/5D-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes primarily in glomeruli Kidney, Ureter, Bladder - urine volume increased Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 60 mg/kg

SEX/DURATION :: female 5-6 week(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 100 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 200 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 400 mg/kg

SEX/DURATION :: female 9-11 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 1200 mg/kg

SEX/DURATION :: female 1-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Maternal Effects - other effects Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

DOSE :: 300 mg/kg

SEX/DURATION :: female 10 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TYPE OF TEST :: DNA inhibition

TEST SYSTEM :: Rodent - rabbit Kidney

DOSE/DURATION :: 6800 ug/L

REFERENCE :: BCPCA6 Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.1- 1958- Volume(issue)/page/year: 38,1771,1989

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes	Xi
Risk Phrases	36/37/38
Safety Phrases	S22-S24/25
RIDADR	NONH for all modes of transport
WGK Germany	2
RTECS	UP0791400
HS Code	2933790090

Precursor 6
75128-73-3 646-06-0 73-40-5 7440-44-0
112233-78-0 1400637-35-5
DownStream 10
502421-44-5 73-40-5 102728-64-3 75128-73-3
110104-37-5 124832-27-5 124832-31-1 114199-19-8
114199-20-1 114199-21-2

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1823380-23-9	1823877-26-4
2137026-85-6	1993318-79-8
1629053-84-4	2708343-15-9
2227843-48-1	1795480-24-8
1824057-21-7	74383-04-3